News & Updates

Results from the phase III KEYNOTE-522 study presented at ESMO 2024 show a statistically significant and clinically meaningful improvement in overall survival (OS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemo alone for previously untreated, high-risk, early-stage triple-negative breast cancer (TNBC).

In the management of severe cancer pain, intravenous patient-controlled analgesia (PCA) with hydromorphone delivers superior pain control with greater patient satisfaction as compared with conventional oral morphine, according to the phase III open-label SYLT-021 study.

Patients with patent foramen ovale (PFO) closure have a greater risk of ischaemic stroke at 4 years than those in the general population, according to a study.

First-line cemiplimab monotherapy continues to provide durable overall (OS) and progression-free survival (PFS) benefits at 5 years compared with chemotherapy in advanced nonsmall cell lung cancer (NSCLC) patients with PD-L1 expression ≥50 percent, according to the results of the EMPOWER-Lung 1 study presented at WCLC 2024.

Hard physical activity and normotensive individuals and increasing systolic blood pressure (SBP) in those with hypertension each correlate with larger thoracic aortic size, suggests a study.

A mild developmental delay may occur following an infection of viral meningitis in preschool children, according to a study, noting that targeted follow-up must be considered.